Boyu Capital
China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
PE-backed WuXi Apptech trades flat on Hong Kong debut
PE-backed WuXi AppTec, a contract pharmaceutical R&D services provider, traded flat on its Hong Kong debut, following an IPO of HK$9.1 billion ($1.1) billion.
PE-backed CStone files for Hong Kong IPO
CStone Pharmaceuticals, a cancer-focused Chinese biopharmaceutical developer with a number of PE and VC backers, has filed for an IPO in Hong Kong.
PE-backed WuXi AppTec targets Hong Kong listing
Wuxi AppTec, a contract pharmaceutical R&D services provider backed by several private equity investors, has filed for a Hong Kong listing less than four months after listing in Shanghai. The size and pricing of the IPO have yet to be decided, but the...
China's Lianlian Payment raises $146m from Sequoia, Boyu
China’s Lianlian Digital, the parent company of payment services provider Lianlian Pay, has raised RMB1 billion ($146 million) from Sequoia Capital China and Boyu Capital in its latest funding round.
Hong Kong's Klook gets $200m Series D
Hong Kong travel services company Klook has closed a $200 million Series D funding round from a group of investors including Sequoia Capital China, Matrix Partners, and Goldman Sachs.
Boyu leads $125m round for Singapore's Trax
Boyu Capital has led a $125 million funding round for Trax, a Singapore-headquartered company that has developed computer vision and analytics solutions through which retailers can link sales to in-store and on-shelf positioning.
Brii Biosciences gets $260m for China expansion
A group of VCs, including Sequoia Capital, have committed $260 million to Brii Biosciences, a China and US-based healthcare start-up executing a number of China-focused growth initiatives.
GIC leads $260m round for China’s CStone Pharma
Singapore’s GIC Private has led a $260 million Series B investment in China’s CStone Pharmaceuticals. The round, completed within two months, is said to be the largest biopharma Series B in the country to date.
Chinese GPs back AstraZeneca spin-out
A consortium led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital will invest up to $250 million in Viela Bio, a pharmaceutical research and development company being spun out from AstraZeneca.
China’s Easyhome raises $2b from Alibaba, PE investors
Alibaba Group has joined a group of PE investors to acquire a 36% interest in Beijing Easyhome Furnishing, China’s second-largest home improvement supplies and furniture chain operator, in a deal worth RMB13 billion ($2 billion).
PE-backed WuXi Biologics completes Hong Kong re-listing
WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 million) IPO.
Boyu acquires 25% of China Vanke's property services unit
Boyu Capital has bought a 25% stake in Vanke Property Development, a wholly-owned property services unit of China Vanke, the second-largest real estate developer in the country, for RMB166 million ($24 million).
PE investors join $1.53b financing round for Baidu’s iQiyi
China’s iQiyi.com, a video-streaming platform majority-owned by search giant Baidu, has raised $1.53 billion from a group of private equity investors through the sale of convertible notes.
PE-backed New Century Healthcare targets $129m HK IPO
New Century Healthcare, a Chinese pediatric hospital operator backed by CDH Investments and Boyu Capital, is planning to raise HK$1 billion ($129 million) via a Hong Kong IPO.
COFCO Meat completes $252m Hong Kong IPO
COFCO Meat, a subsidiary of Chinese agricultural conglomerate COFCO Group that received backing from four private equity firms in 2014, has raised HK$1.95 billion ($252 million) in its Hong Kong IPO, after pricing the offering at bottom of the indicative...
WuXi, Boyu, Oriza commit $150m to China's CStone
WuXi Healthcare Ventures, Oriza Seed Venture Capital, and Boyu Capital have committed $150 million in Series A funding to Chinese bio-pharmaceutical developer CStone Pharmaceuticals.
Telstra completes sale of Autohome stake to Ping An
Australia’s Telstra has closed the sale of a 47.7% interest in Chinese auto services company Autohome to Ping An Insurance Group for $1.6 billion.
Autohome shareholders challenge sale to China's Ping An
Minority shareholders of Chinese auto services company Autohome have filed a petition against a recent move by Telstra to sell the majority of its controlling stake to Ping An Insurance Group for $1.6 billion.
PE consortium battles Ping An for China's Autohome
Boyu Capital, Hillhouse Capital and Sequoia Capital have submitted a take-private offer for Chinese auto listings and information service Autohome. This follows Telstra agreeing to sell its majority stake in the business to Ping An Insurance Group.
China take-privates: New wave
Recent volatility notwithstanding, plenty of investors want to back China take-privates with a view to domestic re-listings at higher valuations. The company founders behind these deals are the big winners
PE consortium completes take-private of China's WuXi PharmaTech
A consortium comprising the founder and CEO of WuXi PharmaTech and several PE investors has completed the privatization of the China-based provider of contract R&D services to global pharmaceutical companies.
WuXi Pharmatech wins endorsement for PE-backed take-private
The proposed privatization of WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has won the support of two major shareholder proxy advisory firms.
China seeing more liquidity, increased competition for deals - AVCJ Forum
China’s private equity industry is seeing greater liquidity than in recent years but competition for deals – the operating partners required to make investments work – is intensifying, GPs told the AVCJ China Forum.